Interval cytoreduction with HIPEC (Hyperthermic Intraperitoneal chemotherapy) signficantly improves Recurrence free survival and overall survival when compared to surgery without HIPEC in stage 3 epithelial ovarian cancer
You can find the abstract here
Results of DESKTOP III ( Progression Free Survival) have been published recently in ASCO Abstracts
The median Progression free survival in patients undergoing secondary cytoreduction for relapsed ovarian cancer (with 6 months plus platinum free interval, positive AGO score ie., ECOG 0,<500 mL Ascites, complete resection at first surgery) was 19.6 months versus 14 months without surgery.
The abstract can be accessed here
Findings from a prospective study has suggested that prophylactic oophorectomy may play a role in prevention of premenopausal breast cancer in BRCA 2 mutation carriers but not in BRCA 1 .
You can find the link to the study here